Work

Insights from the INSIGHTS-ILD Registry: real-world heterogeneity in treatment patterns for patients with fibrotic interstitial lung disease

Year: 2025

Type: editorial

Abstract: Extract Pulmonary fibrosis frequently complicates interstitial lung disease (ILD). While idiopathic pulmonary fibrosis (IPF) remains the prototypic progressive fibrotic ILD, estimates support that up to 40% of individuals with non-IPF fibrotic ILD will develop a progressive fibrosing course [1]. This recognition has led to the recent American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/Asociación Latinoamericana de Tórax clinical practice guideline defining an entity termed progressive pulmonary fibrosis (PPF), with diagnostic criteria designed to capture individuals with declining pulmonary function, progressive fibrotic changes on computed tomography (CT) and worsening respiratory symptoms [2].

Source: ERJ Open Research

DOI: 10.1183/23120541.01395-2024

Authors: Angela Ma, Sydney B. Montesi

Institution: Massachusetts General Hospital

Language: English

Topic: Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $808